Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 20 2025
0mins
Source: PRnewswire
Investigation Announcement: The Ademi Firm is investigating Lava (Nasdaq: LVTX) for potential breaches of fiduciary duty related to its transaction with XOMA Royalty, including concerns over the terms of the deal and the conduct of Lava's board of directors.
Transaction Details: Under the amended agreement, Lava shareholders will receive a reduced initial cash amount of $1.04 per share and a contingent value right, while the minimum net-cash closing condition has been lowered from $31.5 million to $24.5 million, raising concerns about the limitations on competing bids.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
